Article Text

Download PDFPDF
Republished editorial: Targeting lung attacks

Statistics from


  • This is a reprint of a paper that first appeared in Thorax, May 2011, Volume 66, pages 365–6.

  • Competing interests Advisory Boards and Speakers Bureau: GSK, AZ, Merck >$10, 000. BI, Novartis, Nycomed < $10,000. Research funding paid directly to UBC: CIHR GSK, BI, Medimmune, Wyeth, Pharmaxis, Novartis, AllerGen NCE, Genetech, Topigen >$10,000. Member of the GINA Executive and Chair of GINA Science Committee. Member of CTS Asthma committee.

  • Provenance and peer review Not commissioned; not externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.